Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BUB1 | O43683 | 19/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6785575 | 0.89 | ADORA3 (0.53) | — | |
| SCHEMBL14064250 | 0.84 | BUB1 (0.44) | BUB1 | |
| SCHEMBL4252454 | 0.81 | BUB1 (0.49) | BUB1 | |
| SCHEMBL6214026 | 0.81 | BUB1 (0.53) | BUB1 | |
| SCHEMBL14843837 | 0.78 | BUB1 (0.67) | BUB1 | |
| SCHEMBL14064249 | 0.76 | BUB1 (0.44) | BUB1 | |
| SCHEMBL7816730 | 0.76 | BUB1 (0.54) | BUB1 | |
| SCHEMBL14843520 | 0.76 | BUB1 (0.68) | BUB1 | |
| SCHEMBL5777076 | 0.74 | PDE5A (0.48) | — | |
| SCHEMBL29859363 | 0.71 | PDE5A (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023717-A1 | MORPHINE-BRIDGED INDAZOLE DERIVATIVES | FEURER ACHIM | 2009-01-22 | — | — | US | disclosed |
| US-20090023717-A1 | MORPHINE-BRIDGED INDAZOLE DERIVATIVES | FEURER ACHIM | 2009-01-22 | — | — | US | disclosed |
| US-20090023717-A1 | MORPHINE-BRIDGED INDAZOLE DERIVATIVES | FEURER ACHIM | 2009-01-22 | — | — | US | disclosed |
| US-7427617-B2 | Morpoline-bridged indazole derivatives | BAYER HEALTHCARE AG (DE) | 2008-09-23 | — | — | US | disclosed |
| US-20060128700-A1 | e.g. 2-[1-(2-Fluorobenzyl)-1H-indazol-3-yl]-5-(3-oxa-9-azabicyclo[3.3.1]non-9-yl)-4pyrimidinylamine; soluble guanylate cyclase stimulant; neurodegenerative diseases, cognition activator; Alhzeimer's, Parkinson's disease, Pick's syndrome, multiple sclerosis, HIV dementia, schizophrenia | BAYER HEALTHCARE AG (DE) | 2006-06-15 | — | — | US | disclosed |
| EP-1546147-A1 | MORPHOLINE-BRIDGED INDAZOLE DERIVATIVES | Bayer HealthCare AG (DE) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004031186-A1 | MORPHOLINE-BRIDGED INDAZOLE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023717-A1 | MORPHINE-BRIDGED INDAZOLE DERIVATIVES | OPRM1, OPRK1, OPRD1 | BUB1 4507/4885 |
| US-20060128700-A1 | e.g. 2-[1-(2-Fluorobenzyl)-1H-indazol-3-yl]-5-(3-oxa-9-azabicyclo[3.3.1]non-9-yl)-4pyrimidinylamine; soluble guanylate cyclase stimulant; neurodegenerative diseases, cognition activator; Alhzeimer's, Parkinson's disease, Pick's syndrome, multiple sclerosis, HIV dementia, schizophrenia | GUCY1B2, COG4, GUCY1A2 | BUB1 4090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.